A FORMULATION COMPRISING OF SYMPLOSOSIDE DERIVATIVES THAT ARE CHARACTERIZED BY TRIGGERING ENDOGENOUS PROTEIN KINASE PKR AND RNASE L EXPRESSION
Creators: name: Alkoclar, Erdal Can
Publisher: name: Zenodo
Year: 2020
Subjects: Rnase L Expression Interferon Gamma Antiviral Symplososide

description: <strong>Field of Invention</strong> The present invention herewith discloses a formulation developed to display a characteristic of triggering endogenous protein kinase pkr and rnase l expression <strong>Background of the Related Technology</strong> At present it is known that the main component which forms the cells of living things are composed amino acid compounds that contain elements like sulphur, oxygen and carbon in general. It is a natural substance of complex structure, found in nutrients like egg white, meat, milk etc. ATP or another nucleoside that catalyzes addition of a phosphate group to the specific amino acids of protein, like serine, threonine, tyrosine, is an enzyme that transfers the last phosphate group of triphosphate to the side chain of Ser, Thr, Tyr, Asp or His of the target protein and thus regulates the activity or other properties of a protein. In state of art technology, invention no “WO 1998/039487", with title “Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication" and under classification number “C12Q 1/70" discloses a novel method for identifying antiviral agents which selectively interfere with viral proteins that override interferon-induced cellular defense mechanisms against viral infection. Screening assays are disclosed which identify agents which selectively inhibit the interaction between viral proteins containing an interferon sensitivity determining region, and interferon-induced PKR protein kinase Again invention no “EP1957061B1", with title “Combination comprising at least one amino acid and a pkr inhibitor for use in the treatment of muscle loss" and under classification number “A61K 31/429" discloses methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof. The invention further provides nutritional products for such administration, including orally-administrable nutritional products Again invention no “EP1736153B1", with title “Secretin-receptor ligands in the treatment of cystic fibrosis (CF)" and under classification number “A61K 31/24" discloses a compositions which comprise camostat together with at least one other compound active against cystic fibrosis (CF), wherein this other compound action against CF is chosen from hedocromil or from mucoltylic agents such as acetylcysteine, deoxyribonuclease I (dornase) or erdosteine. To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation that is characterized by triggering endogenous protein kinase pkr and rnase l expression <strong>Objective of the Invention</strong> To overcome the disadvantages experienced in state of art technology; One objective of the present invention is to trigger increase in production of protein kinase pkr, which is an endogenous antiviral enzyme. One other objective of the invention is to trigger increase in expression of rnase I, which is an endogenous antiviral enzyme. One other objective of the invention is to trigger increase in expression capacity of gamma-interferon mrna of t cells. The present invention which is aimed to achieve the above-mentioned advantages, is related to a formulation that is characterized by triggering endogenous protein kinase pkr and rnase l expression and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 7-beta symplososide, 11-alpha-l-rhamnosyl-symplososide. Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith. <strong>Detailed Description of the Invention</strong> The present herewith discloses a formulation comprising of symplososide derivatives that are characterized by triggering endogenous protein kinase pkr and rnase l expression. Referred formulation triggers increase in production of protein kinase pkr, which is an endogenous antiviral enzyme, triggers increase in expression of rnase I, which is an endogenous antiviral enzyme, trigger increase in expression capacity of gamma-interferon mrna of t cells. The formulation of the invention presented herewith contains; 7-beta symplososide, 11-afha-l-rhamnosyl-symplososide . The referred formulation is formed by mixing the above-mentioned components at below percentages by weight; 1-99% of 7-beta symplososide, 99-1% of 11-afha-l-rhamnosyl-symplososide. Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof. The present invention at the same time discloses using the above-referred formulation which displays the characteristic of triggering endogenous protein kinase pkr and rnase l expression and manufacturing it for such purpose. <strong>CLAIMS</strong> A formulation intended to display characteristic of triggering endogenous protein kinase pkr and rnase l expression, which consists of combining the components selected from the group; 7-beta symplososide, 11-afha-l-rhamnosyl-symplososide in a single form or in combinations thereof The formulation of Claim 1 which is characterized by containing 1-99% of 7-beta symplososide by weight. The formulation of Claim 1 which is characterized by containing 99-1% of 11-afha-l-rhamnosyl-symplososide by weight. Using the compositions obtained by selecting singly or in combination of components from the group of; 7-beta symplososide, 11-afha-l-rhamnosyl-symplososide from any one as given in Claims 2-3 in manufacturing the formulation intended to display a characteristic of triggering endogenous protein kinase pkr and rnase l expression. <strong>SUMMARY</strong> <strong>A FORMULATION COMPRISING OF SYMPLOSOSIDE DERIVATIVES THAT ARE CHARACTERIZED BY TRIGGERING ENDOGENOUS PROTEIN KINASE PKR AND RNASE L EXPRESION</strong> The present herewith discloses a formulation comprising of symplososide derivatives that are characterized by triggering endogenous protein kinase pkr and rnase l expression. Referred formulation triggers increase in production of protein kinase pkr, which is an endogenous antiviral enzyme, triggers increase in expression of rnase I, which is an endogenous antiviral enzyme, trigger increase in expression capacity of gamma-interferon mrna of t cells.